Compare Cytokinetics Inc (CYTK) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while YieldMax MSTR Option Income Strategy ETF trades at $15.84 (market cap $1.11B). The key difference: Cytokinetics Inc is far larger — about 7.8× YieldMax MSTR Option Income Strategy ETF's market cap, and Cytokinetics Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and YieldMax MSTR Option Income Strategy ETF for 30 Days on average.
| CYTK | MSTY | |
|---|---|---|
Market Cap | $8.62B | $1.11B |
Volume | 2,594,626 | 3,805,384 |
Sector | Health | Income / Options Overlay |
52-Week High | $87.26 | $67.85 |
52-Week Low | $54.76 | $11.55 |
Typical Hold Time | 19 Days | 30 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
MSTY, the YieldMax MSTR Option Income Strategy ETF, trades at $15.83, down 5.61% with a bearish technical signal. The fund generates weekly distributions through options strategies on MicroStrategy stock, with recent payouts ranging from $0.16 to $0.34. Despite high distribution rates exceeding 100% annualized, the fund has experienced significant NAV erosion, declining approximately 34% over six months according to 24/7 Wall Street analysis from July 2026.
The outlook remains challenging as MSTY's strategy sacrifices capital appreciation for income generation. While the high distribution rate provides income, the structural erosion of NAV presents substantial risk. Investors face the dual challenge of receiving taxable distributions while experiencing principal decline, making this suitable only for those prioritizing current income over capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
